17:11 , Apr 5, 2019 |  BC Week In Review  |  Company News

Atlas' build-to-buy Arteaus sells Emgality royalties for $260M

Arteaus sold its royalty rights for Lilly's Emgality galcanezumab-gnlm to Royalty Pharma (New York, N.Y.) for $260 million. Atlas Ventures and OrbiMed Advisors launched Arteaus Therapeutics LLC in October 2011 with $18 million to develop...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
08:00 , Jan 11, 2016 |  BioCentury  |  Strategy

Set them free

In a week where Atlas Venture announced two additions to its growing stable of prenegotiated build-to-buy deals, Johnson & Johnson is bucking the trend with a new program for out-licensing assets that in some cases...
02:24 , Feb 5, 2015 |  BC Extra  |  Company News

The Medicines Co. acquires Annovation

The Medicines Co. (NASDAQ:MDCO) exercised its option to acquire Annovation Biopharma Inc. (Cambridge, Mass.) for $28.4 million in cash up front. Annovation shareholders are eligible for up to $26.3 million in clinical and regulatory milestones,...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

Atlas' next chapter

After separating from the tech group, Atlas Venture 's healthcare team plans to stick to the early stage investing strategy the firm says has provided returns in the top quartile of life science VCs. For...
07:00 , May 1, 2014 |  BC Innovations  |  Strategy

Scripps looks outward

The Scripps Research Institute has borrowed a page from the VC playbook and formed a separate corporation called Scripps Advance LLC that will house assets and IP related to discrete early stage research projects. The...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Arteaus Therapeutics, Eli Lilly deal

Eli Lilly exercised its option to reacquire LY2951742 from Arteaus at prenegotiated, undisclosed terms after the compound met the primary and secondary endpoints in a proof-of-concept (POC) Phase II trial to prevent frequent recurrent migraines....
08:00 , Jan 20, 2014 |  BioCentury  |  Finance

Asset-centric milestone

Atlas Venture and Eli Lilly and Co. both checked first-time milestones when the pharma decided to reacquire its anti- CGRP antibody for migraine prevention from Arteaus Therapeutics LLC . Last week, Lilly exercised its option...
02:02 , Jan 14, 2014 |  BC Extra  |  Company News

Lilly regains migraine compound from Atlas' Arteaus

Eli Lilly and Co. (NYSE:LLY) exercised its option to reacquire LY2951742 from Arteaus Therapeutics LLC (Cambridge, Mass.) at prenegotiated, undisclosed terms after the compound met the primary and secondary endpoints in a proof-of-concept (POC) Phase...
07:00 , May 20, 2013 |  BioCentury  |  Finance

A little less lumpy

A little less lumpy Atlas Venture recruited Amgen Inc. and Novartis AG as more than just new LPs in its ninth fund - the VC hopes closer ties with the companies will deliver useful feedback...